Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1987-9-25
pubmed:abstractText
A multicentre study with 622 patients has been undertaken to evaluate the efficacy of cyclandelate 1600 mg daily in the treatment of vertigo of circulatory origin in general practice. The characteristics of the patient population were consistent with the diagnosis of vertigo of circulatory origin. Patients with some risk factors, essentially a history of thrombosis and atherosclerotic patients, had more severe symptoms at the onset of the study. During the 3-month period of treatment with cyclandelate, the average global score of vertigo (0-10) decreased from 5.57 to 2.12 and the average scores of frequency, severity and duration of vertigo (0-4) decreased from 2.53, 2.55 and 2.26 to 0.98, 0.89 and 0.84, respectively. Patients previously treated with other anti-ischaemic drugs had similar responses compared to other patients. These results indicate that cyclandelate may be useful in the management of vertigo of circulatory origin in general practice.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0012-6667
pubmed:author
pubmed:issnType
Print
pubmed:volume
33 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
114-9
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
Cyclandelate in the treatment of vertigo of circulatory origin. A study in general practice.
pubmed:publicationType
Journal Article